RWE Resource Abstract

Linking reimbursement to patient-reported quality of life: Provider perspectives. J Clin Oncol 2020: 38, no. 29_suppl, 75-75.

Feinberg BA, Jeune-Smith Y, Fortier S, Yeh T, Kish J, Gajra A.

Poster available upon request.

Read the abstract

The use of validated geriatric assessment instruments among US community oncologists. J Clin Oncol 2020: 38, no. 29_suppl, 129-129.

Gajra A, Jeune-Smith Y, Fortier S, Feinberg BA.

Poster available upon request.

Read the abstract

Patient-reported outcomes in routine oncology care: Perceptions, execution, and barriers. J Clin Oncol 2020: 38, no. 29_suppl, 162-162.

Gajra A, Jeune-Smith Y, Yeh T, Fortier S, Feinberg BA.

Poster available upon request.

Read the abstract

Knowledge and evaluation of geriatric assessment (GA) domains among U.S. community oncologists/hematologists (cOH). J Clin Oncol 2020: 38, no. 29_suppl, 206-206.

Gajra A, Fortier S, Jeune-Smith Y, Feinberg BA.

Poster available upon request.

Read the abstract

Treatment Patterns of Advanced or Recurrent Endometrial Cancer Following Platinum-Based Therapy in the US Real-World Setting. J Clin Oncol 2020: 38, no. 15_suppl. e18036.

Klink AJ, DeMars L, Huang J, Maiese EM, Feinberg BA, Hurteau J.

Poster available upon request.

Read the abstract

Gender-based disparities in clinical trials supporting FDA approval of oncology drugs. J Clin Oncol 2020: 38 no. 15_suppl., 2058.

Zettler M, Feinberg BA, Kish J, Gajra A.

Poster available upon request.

Read the abstract

Impact of augmented intelligence (AI) on utilization of palliative care (PC) services in oncology. J Clin Oncol 2020: 38 no. 15_suppl., 12015.

Gajra A, Zettler M, Kish J, Miller K, Frownfelter J, Valley AW, Blau S.

Poster available upon request.

Read the abstract

Impact of augmented intelligence (AI) on identification and management of depression in oncology. J Clin Oncol 2020: 38 no. 15_suppl., e14059.

Frownfelter J, Blau S, Zettler M, Miller K, Kish J, Valley AW, Gajra A.

Poster available upon request.

Read the abstract

RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma. J Clin Oncol 2020: 38, no. 15_suppl 8020-8020.

Nowakowski G, Rodgers T, Marino D, Frezzato M, Barbui A, Castellino C, Meli E, Fowler N, Feinberg BA, Tillmanns S, Parche S, Fingerle-Rowson G, Winderlich M, Ambarkhane S, Salles G, Zinzani P.

Poster available upon request.

Read the abstract

RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma. EHA 2020, abstract S238.

Zinzani P, Rodgers T, Marino D, Frezzato M, Barbui A, Castellino C, Meli E, Fowler N, Feinberg BA, Tillmanns S, Parche S, Fingerle-Rowson G, Winderlich M, Ambarkhane S, Salles G, Nowakowski G.

Oral presentation available upon request.

Read the abstract

Prescribing preferences for hormone sensitive (HR+) metastatic breast cancer (mBC) in the CDK 4/6 inhibitor (CDK 4/6i) era. J Clin Oncol 2020: 38, no. 15_suppl, e13058.

Feinberg BA, Wojtynek J, Dokubo I, Jeune-Smith Y, Kish J, Gajra A.

Read the abstract

Physician treatment preferences for metastatic triple negative breast cancer (mTNBC) in an era of immunotherapy. J Clin Oncol 2020: 38, no. 15_suppl, e13095.

Gajra A, Wojtynek J, Dokubo I, Jeune-Smith Y, Kish J, Feinberg BA.

Read the abstract

Differences in real-world (RW) non-small cell lung cancer (NSCLC) treatment patterns among people living with HIV/AIDS (PLWHA) compared to those without HIV/AIDS (PWoHA). J Clin Oncol 2020: 38, no. 15_suppl, 7070-7070.

Klink AJ, Falkenstein A, Gajra A.

Poster available upon request.

Read the abstract

Real-World Outcomes of Pembrolizumab Plus Carboplatin Plus Paclitaxel or Nab-Paclitaxel in Non-Small Cell Lung Cancer (NSCLC). J Clin Oncol 2020: 38, no. 15_suppl, e21717.

Tabah A, Huggar D, Kish J, Bapat B, Liassou D, Gajra A, Miller T, Copher R, Patel M.

Read the abstract

Differences in real-world liver cancer treatment patterns among people living with HIV/AIDS (PLWHA) compared to those without HIV/AIDS (PWoHA). J Clin Oncol 2020: 38, no. 15_suppl, e19010.

Falkenstein A, Klink AJ, Gajra A.

Read the abstract

Low value care in oncology: US oncologists’ perceptions. Value in Health 2020: 23 (Supplement 1), S62.

Gajra A, Kish JK, Graham Russell AC, Klink AJ, Mehta S, Feinberg B.

Read the abstract

Avoidable waste in oncology care delivery: perceptions of US hematologists/oncologists. Value in Health 2020: 23 (Supplement 1), S60-S61.

Gajra A, Klink AJ, Kish JK, Graham Russell AC, Feinberg B.

Read the abstract

Disparities in Cancer Care: The Unmet Need for Geriatric Patients. Value in Health 2020: 23 (Supplement 1), S65–S66.

Gajra A, Zettler M, Jeune-Smith Y, Feinberg B.

Read the abstract

Community Oncologists Perceptions Three Years after the Oncology Care Model. J Clin Oncol 2019: 37, no. 27_suppl, 113-113.

Kish, J, Yeh T, Gajra A, Smith Yolaine, Feinberg BA.

Poster available upon request.

Read the abstract

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices. Blood 2019: 134 (Supplement 1): 4057.

Gajra A, Klink AJ, Nabhan C, Feinberg BA.

Poster available upon request.

Read the abstract

Potential of 2018 ASH CLL Data to Alter Standard of Care for Initial CLL Treatment. Blood 2019: 134 (Supplement 1): 5816.

Feinberg BA, Sweat R, Jeune-Smith Y, Gajra A.

Read the abstract

Perceptions of Community Hematologists/Oncologists on the Potential of Data Presented at ASH 2018 and ASCO 2019 to Alter the Standard of Care for Multiple Myeloma Treatment. Blood 2019: 134 (Supplement 1): 5822.

Gajra A, Sweat R, Jeune-Smith Y, Feinberg BA.

Read the abstract

Gajra A, Sweat R, Jeune-Smith Y, Kish JK, Feinberg BA. Perceptions of Community Hematologists/Oncologists on Barriers to Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Diffuse Large B-Cell Lymphoma. Blood 2019: 134 (Supplement 1): 2198.

Gajra A, Klink AJ, Chopra D, Feinberg BA.

Poster available upon request.

Read the abstract

Real-World Utilization of Midostaurin Among Patients with Systemic Mastocytosis (SM). Blood 2019: 134 (Supplement 1): 5378.

Gajra A, Klink AJ, Chopra D, Feinberg BA.

Read the abstract

Real-World Utilization of Midostaurin Among Patients with Acute Myeloid Leukemia (AML). Blood 2019: 134 (Supplement 1): 5135.

Gajra A, Klink AJ, Kish JK, Chopra D, Feinberg BA.

Read the abstract

Real-World Dosing and CBC Monitoring in Patients with Metastatic Breast Cancer during Palbociclib plus Letrozole therapy. Cancer Res. 2019: 80(4) Supplement, P5-14-13.

Kish J, Miller T, Nero D, Liassou D, Liu X, McRoy L, Feinberg B, Zhan L, Trocio J.

Poster available upon request.

Read the abstract

Adverse Events in Elderly Hodgkin Lymphoma Patients Treated with Pembrolizumab or Nivolumab in the Real World. Blood 2019: 134 (Supplement 1), 3490.

Zettler ME, Nabhan C, Gajra A, Feinberg BA.

Poster available upon request.

Read the abstract

Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients. Blood 2019: 134 (Supplement 1), 1952.

Gajra A, Zettler ME, Phillips EG, Klink AJ, Kish JK, Mehta S, Feinberg BA.

Poster available upon request.

Read the abstract

Real-World Analysis of Adverse Events Associated with CAR T-Cell Therapy Among Adults Age ≥65 Years. Blood 2019: 134 (Supplement 1), 1951.

Zettler ME, Feinberg BA, Phillips EG, Klink AJ, Mehta S, Gajra A.

Poster available upon request.

Read the abstract

Use of health economics and outcomes research to inform treatment decisions among US oncologists. Value in Health 2019: 22 (Supplement 3), S535.

Bapat B, Klink A, Graham Russell A, Jeune-Smith Y, Feinberg BA.

Poster available upon request.

Read the abstract

Comparative effectiveness among single agent chemotherapeutics in the treatment of TNBC using time to next treatment as a surrogate for efficacy. Value in Health 2019: 22 (Supplement 3), S406.

Feinberg BA, Kish J, Dokubo I, Wojtynek J, Lord K.

Oral presentation available upon request.

Read the abstract

The impact of value-based care on oncology specialty physicians. Value in Health 2019: 22 (Supplement 3), S493.

Lord K, Feinberg BA, Klink A, Kish JK, Yeh TC, Phillips Jr EG.

Poster available upon request.

Read the abstract

Real-world outcomes with multiple second-line treatments after first-line lenvatinib in patients with radioactive iodine refractory differentiated thyroid cancer (RAIR DTC). Thyroid. 2019:P-1-A-166, 388.

Chatterjee D, Kish J, Wang EC, Misir S, Myerscough C, Liassou D, Feinberg B.

Poster available upon request.

Read the abstract

Real-world data describing the role of chemotherapy in the treatment of HR+/HER2- MBC patients: divergence from evidence-based medicine. Value in Health 2019: 22 (Supplement 3), S499.

Feinberg BA, Kish J, Dokubo I, Wojtynek J, Lord K.

Poster available upon request.

Read the abstract

Physician acceptance of real-world evidence in drug approval and labeling. Value in Health 2019: 22 (Supplement 3), S540.

Kish JK, Feinberg BA, Jeune-Smith Y.

Poster available upon request.

Read the abstract

Perceptions of and participation in real-world evidence research among US community oncologists. Value in Health 2019: 22 (Supplement 3), S533.

Klink A, Bapat B, Graham Russell A, Jeune-Smith Y, Feinberg BA.

Poster available upon request.

Read the abstract

Making the case for EGFR TKI sequencing in EGFR-mutated (EGFRm+) NSCLC: a GioTag study US patient analysis. AMCP-Nexus 2019.

Halmos B, Gucalp R, Tang W, Märten A, Moehring B, Feinberg B, Hochmair MJ.

Poster available upon request.

Real-world effectiveness of first-line palbociclib + letrozole for metastatic breast cancer 4 years post approval in the US. Ann Oncol 2019: 30 (Supplement 5), V120-V121.

Kish J, Trocio J, Miller T, Nero D, Liassou D, Liu X, McRoy L, Feinberg B.

Poster available upon request.

Read the abstract

Scope of practice of advanced practice providers (APP) in US community oncology. J Clin Oncol 2019:37, no. 15_suppl, 6646-6646.

Klink A, Bapat B, Smith Y, Nabhan C, Feinberg BA.

Poster available upon request.

Read the abstract

Frequency and causes of oncologists’ burnout in community practices. J Clin Oncol 2019:37, no. 15_suppl, e18375.

Nabhan C, Bapat B, Smith Y, Klink A, Feinberg BA.

Read the abstract

Community oncologists perceptions and readiness to implement Medicare Access and CHIP Reauthorization Act (MACRA). J Clin Oncol 2019:37, no. 15_suppl, e18374.

Bapat B, Smith Y, Klink A, Nabhan C, Feinberg BA.

Read the abstract

Cancer Patient Engagement in 2018 – Community Providers Perspectives on Digital Data and Communication at the Bedside. Value in Health 2019: 22 (Supplement 2), S101.

Kish JK, Johnson C, Nabhan C, Sweat R, Jeune-Smith Y, Feinberg BA.

Poster available upon request.

Read the abstract

Use of a granulocyte colony-stimulating factor for the prevention of febrile neutropenia in the era of value-based care. J Clin Oncol 2019:37, no. 15_suppl, e12601.

Feinberg BA, Lord K, Kish J, Laney J, Chopra D, Liassou D.

Read the abstract

Real-world evidence evaluation of the use of single versus combination chemotherapy in salvage therapy for metastatic breast cancer. J Clin Oncol 2019:37, no. 15_suppl, e12600.

Feinberg BA, Lord K, Kish J, Laney J, Chopra D, Liassou D.

Read the abstract

Real-world evidence evaluating the use of an NK-1 antiemetic in the systemic chemotherapy treatment of metastatic breast cancer. J Clin Oncol 2019:37, no. 15_suppl, e12599

Lord K, Feinberg BA, Kish J, Laney J, Chopra D, Liassou D.

Read the abstract

Utilization and outcomes of eribulin mesylate Post a cyclin-dependent kinase 4/6 inhibitor: an observational real-world study in United States community oncology practices (EMPOWER). Ann Oncol 2019: 30 (Supplement 3), III54.

Mougalian SS, Wang E, Alexis K, Feinberg BA, Nero D, Miller T, Laney J, Chatterjee D, Knoth RL, Kish JK.

Poster available upon request.

Read the abstract

Utilization and outcomes of eribulin mesylate Post a cyclin-dependent kinase 4/6 inhibitor: an observational real-world study in United States community oncology practices (EMPOWER). MBCC 2019.

Mougalian SS, Wang E, Alexis K, Feinberg BA, Nero D, Miller T, Laney J, Chatterjee D, Knoth RL, Kish JK.

Poster available upon request.

Real-World Incidence and Cost Assessment of Pneumonitis During Chemoradiotherapy for Locally Advanced, Non-small Cell Lung Cancer Patients. JMCP 2019: Vol. 25, No. 3-a, S74.

Ryan K, Nero D, Feinberg BA, Lee C, Kish JK, Seal B.

Poster available upon request.

Read the abstract

Physician Treatment Choice in Treating and Managing Patients with Advanced Hepatocellular Carcinoma (aHCC) in the US Community Oncology Practice. JMCP 2019: Vol. 25, No. 3-a, S25.

Klink AJ, Marshall A, Gricar J, Wisniewski T, Sill B, Savidge R, Beata Korytowsky, Kaufman J, Laney J, Chung J, Myerscough C, Feinberg BA.

Poster available upon request.

Read the abstract

Healthcare Resource Utilization in First-Line Immunotherapies For Patients with Metastatic Melanoma. J Clin Oncol 2019: 37, no. 8_suppl, 137-137.

Liu F, Klink A, Feinberg BA, Ahsan S, Nero D, Chmielowski B.

Poster available upon request.

Read the abstract

Healthcare Resource Utilization and Costs in Patients Treated with Systemic Therapies in Metastatic Melanoma. JNCCN 2019: 17(3.5), HSR19-095.

Klink A, Feinberg BA, Liu F, Ahsan S, Nero D, Chmielowski B.

Poster available upon request.

Read the abstract

Real-world time to next treatment (TTNT) for first-line (1L) targeted and immuno-oncology therapies for BRAF-mutated metastatic melanoma (MM) by lactate dehydrogenase (LDH) level. J Clin Oncol 2019: 37, no. 8, 141-141.

Luke J, Ghate SR, Kish JK, Lee CH, Nidife B, McAllister L, Mehta S, Nakasato AR, Feinberg BA.

Poster available upon request.

Read the abstract

Patient-reported outcome labeling for malignant hematology drugs approved in the United States: 2011-2017. Blood 2018: 132 (Suppl 1), 2292.

Zettler M, Basch E, Nabhan C.

Poster available upon request.

Read the abstract

A case study in Choosing Wisely recommendation adoption: single fraction radiation treatment of bone metastases. Value in Health 2018: 21 (Supplement 3), S356.

Feinberg BA, Laney J, Chung J, Nero D, DuPont J.

Poster available upon request.

Read the abstract

Treatment patterns in recurrent or metastatic squamous cell carcinoma of head and neck (R/M SCCHN) post platinum-based therapy (PPBT) in the immuno-oncology (IO) era. Value in Health 2018: 21 (Supplement 3), S56.

Radtchenko J, Korytowsky B, Abraham P, Singh P, Feinberg BA.

Poster available upon request.

Read the abstract

Impact of Comorbid Depression on Rates, Costs, and Health Care Resource Use in Lung Cancer Patients. Value in Health 2018: 21 (Supplement 3), S48.

Merritt N, Chung J, Kish J, Nabhan C, Feinberg B.

Poster available upon request.

Read the abstract

Impact of Comorbid Depression on Rates, Costs, and Health Care Resource Use in Breast Cancer Patients. Value in Health 2018: 21 (Supplement 3), S48.

Chung J, Merritt N, Kish J, Nabhan C, Feinberg B.

Poster available upon request.

Read the abstract

Outcomes of peripheral t-cell lymphoma (PTCL) patients treated in the real world. Value in Health 2018: 21 (Supplement 3), S71.

Shah P, Klink A, Welles S, Nabhan C.

Poster available upon request.

Read the abstract

Predictors of hospitalizations and emergency department (ED) visits in second-line (2L) advanced non-small cell lung cancer (ANSCLC). Value in Health 2018: 21 (Supplement 3), S61.

Korytowsky B, Radtchenko J, Nwokeji E, Tuell K, Feinberg BA.

Poster available upon request.

Read the abstract

Medication therapy management with direct patient engagement to address non-adherence to specialty drugs. Value in Health 2018: 21 (Supplement 3), S321.

Feinberg B, Burruss RA, Arikian V, Jaster R, Oleru K, Traurig T, Merritt N, Nabhan C.

Poster available upon request.

Read the abstract

Patterns of care and treatment outcomes for real-world liposarcoma (LP) and leiomyosarcoma (LM) patients treated at US-based community oncology practices. JMCP 2018:24, No. 10-a, S24.

Kish JK, Copher R, Wang E, Lee C, Chatterjee D, McAllister L, Yu H, Feinberg BA.

Poster available upon request.

Read the abstract

Real-world (RW) predictors of immunoncology (IO) vs chemotherapy (C) use in advanced non-small cell lung cancer (aNSCLC). J Thorac Oncol 2018:13(10) Supplement, S889.

Radtchenko J, Korytowsky B, Nwokeji E, Tuell K, Feinberg BA.

Poster available upon request.

Read the abstract

Real-World Dosing Patterns among Metastatic Breast Cancer Patients Initiating First Line (1L) Palbociclib (PAL) Therapy. J Clin Oncol 2018: 36, no. 15_suppl, e13050.

Nero D, Feinberg BA, Yu HT, McRoy L, Mardekian J, Chung J, Trocio J.

Read the abstract

Objective Response Rate (ORR) and Time to Treatment Failure (TTF) for BRAF v600 Mutated Metastatic Melanoma (BRAF+ MM) Patients Receiving First-Line (1L) Treatment with Dabrafenib/Trametinib (D+T) v Ipilimumab/Nivolumab (I+N) and Nivolumab or Pembrolizumab (N/P) Monotherapy at US-based Community Oncology Practices. J Clin Oncol 2018: 36, no. 15_suppl, e21538.

Feinberg BA, Kish J, Ghate S, Ndife B, Lee C, McAllister L, Mehta S, Nakasato A, Luke J.

Read the abstract

Objective Response Rate (ORR) and Time to Treatment Failure (TTF) for BRAF v600 Mutated Metastatic Melanoma (BRAF+ MM) Patients Receiving First-Line (1L) Targeted Therapy (TT) or Immuno-Oncology (I-O) Agents at US-based Community Oncology Practices. J Clin Oncol 2018: 36, no. 15_suppl, E21516.

Luke J, Ghate S, Kish J, Lee C, McAllister L, Mehta S, Ndife B, Feinberg BA.

Read the abstract

Hospitalizations and emergency department (ED) visits pre- and post-approval of immunooncology agents (IO) in advanced non-small cell lung cancer (aNSCLC). J Clin Oncol 2018: 36, no. 15_suppl, e21006.

Radtchenko J, Korytowsky B, Nwokeji E, Tuell K, Feinberg BA.

Read the abstract

Value-Based Care in Oncology: Challenges and Barriers Amongst Community Oncologists. Value in Health 2018: 21, Supplement 1, S41-S42.

Nabhan C, Smith-Jeune Y, Klink A, Kish J, Feinberg BA.

Poster available upon request.

Read the abstract

Validation of a claims-based algorithm for identification of patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) in the US. Value in Health 2018: 21, Supplement 1, S218.

Korytowsky B, Radtchenko J, Abraham P, Klinefelter P, Shaw JW, Feinberg B.

Poster available upon request.

Read the abstract

Use of Real-World Evidence in Clinical Decision Making by Community Oncologists. Value in Health 2018: 21, Supplement 1, S48.

Kish J, Feinberg B, Hua D, Tchafa A, Smith Y, Klink A, Nabhan C.

Poster available upon request.

Read the abstract

Impact of human papillomavirus (HPV) etiology and immuno-oncology therapy (IO) availability on the patient journey in squamous cell carcinoma of the head and neck (SCCHN). Value in Health 2018: 21, Supplement 1, S137.

Korytowsky B, Radtchenko J, Abraham P, Klinefelter P, Shaw JW, Feinberg B.

Poster available upon request.

Read the abstract

Cost of care in advanced non-small cell lung cancer (ANSCLC) in the immuno-oncology (IO) era: a real-world analysis of early data. Value in Health 2018: 21, Supplement 1, S122-S123.

Radtchenko J, Korytowsky B, Nwokeji E, Tuell K, Feinberg B.

Poster available upon request.

Read the abstract

Community Oncology Perceptions and Views on Genomic Testing in the Era of Precision Oncology. Value in Health 2018: 21, Supplement 1, S42.

Nabhan C, Smith-Jeune Y, Klink A, Kish J, Feinberg BA.

Poster available upon request.

Read the abstract

Adherence of outpatient cancer patients to oral oncolytic medications provided by a specialty pharmacy. Value in Health 2018: 21, Supplement 1, S35.

Feinberg BA, Burruss RA, Arikian V, Jaster R, Oleru K, Traurig T.

Poster available upon request.

Read the abstract

A Comparison of Retrospective Database Analysis with Chart Review in Patients Receiving Somatostatin Analog in Neuroendocrine Tumors. 15th Annual ENETS conference, 2018: 2160.

Klink A, Feinberg BA, Yu H, Ray D, Pulgar S, Phan A, Vinik A.

Poster available upon request.

Read the abstract

US Community Rheumatologists’ Knowledge and Perceptions of Biosimilar Expanded Indication Approval by Extrapolation. Arthritis Rheumatol. 2019: 71 (suppl 10), 1118.

Yeh TC, Jeune-Smith Y, Phillips Jr E, Gajra A, Feinberg B.

Poster available upon request.

Read the abstract

Current patterns of care in the assessment and treatment of patients with rheumatoid arthritis (RA). Value in Health 2019: 22 (Supplement 3), S703-S704.

Bapat B, Klink A, Kaufman J, Lobo F, Han X, Szymialis R, Tuell K, Feinberg BA.

Poster available upon request.

Read the abstract

ACPA Testing and Resultant Treatment Patterns in Patients with Rheumatoid Arthritis: Findings from US Community Rheumatology Practices. Arthritis Rheumatol. 2019; 71 (suppl 10), 2353.

Bapat B, Klink AJ, Kaufman J, Lobo F, Han X, Ferri L, Szymialis R, Poretta T, Feinberg B.

Poster available upon request.

Read the abstract

Real-World Distribution of Anti-Cyclic Citrullinated Peptide Concentrations and Impact on Treatment Patterns of Patients with Rheumatoid Arthritis. Arthritis Rheumatol. 2019; 71 (suppl 10), 2352.

Klink AJ, Bapat B, Kaufman J, Lobo F, Han X, Ferri L, Szymialis R, Poretta T, Feinberg B.

Poster available upon request.

Read the abstract

Perceptions Among Community Oncologists and Rheumatologists on Direct to Consumer Advertising (DTCA) in Healthcare. Value in Health 2019: 22 (Supplement 2), S316-S317.

Phillips E, Kish JK, Nabhan C, Jeune-Smith Y, Feinberg BA.

Poster available upon request.

Read the abstract

Community rheumatologists' experience and views on non-medical switching to biosimilars. Value in Health 2019: 22 (Supplement 2), S390.

Klink A, Yeh T, Jeune-Smith Y, Phillips Jr EG, Feinberg BA.

Poster available upon request.

Read the abstract

Real-world (RW) treatment patterns of rheumatoid arthritis (RA) patients who switched from REMICADE® (infliximab) to INFLECTRA® (infliximab-dyyb). JMCP 2019: Vol. 25, No. 3-a, S81-S82.

Klink AJ, Sadik K, Lee C, Ellis L, Feinberg BA.

Poster available upon request.

Read the abstract

Choice of initial biologic DMARD impacts healthcare resource use among patients with rapidly progressing RA. Ann Rheum Dis 2018:77, Suppl, A528.

Klink A, Tuell K, Szymialis R, Curtice T, Gupta K, Nero D, Feinberg B.

Poster available upon request.

Read the abstract

Assessing Readiness of US Community Rheumatologists for Implementation of Medicare Access and CHIP Reauthorization Act (MACRA), Merit-Based Incentive Payment System (MIPS) and Alternative Patient Models (APMS). Value in Health 2018: 21, Supplement 1, S90.

Radtchenko J, Nabhan C, Jeune-Smith Y, Feinberg B.

Poster available upon request.

Read the abstract

Recent real-world trends in management of systemic lupus erythematosus (SLE) by US community rheumatologists. Value in Health 2018: 21, Supplement 1, S265.

Radtchenko J, Pallett P, Stockton CM, Feinberg BA.

Poster available upon request.

Read the abstract

Patient-Centered Medicine Model to Mitigate Prior Authorization Impact on Patients With Rheumatoid Arthritis (RA). JMCP 2018: Vol. 24, No. 4-a, S84.

Feinberg B, Jeune-Smith Y, Drenning JA.

Poster available upon request.

Read the abstract

Linking physician survey to claims via NPI to explain drug selection preferences in treating retinal disease. ISPOR EU 2018.

Chung J, Tchafa A, Smith Y, Kish J, Rashid N, Nabhan C, Feinberg B.

Poster available upon request.

Demographic, Payer, and Clinical Characteristics of Patients Receiving Bevacizumab (BEV) and Ranibizumab (RAN) for Treatment of Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME). Value in Health 2018: 21, Supplement 1, S243.

Chung J, Radtchenko J, Nero D, Nabhan C, Kish J, Feinburg B.

Poster available upon request.

Read the abstract

Reports of Coronary Stent Fracture from the Food and Drug Administration Manufacturer and User Facility Device Experience Database, 2013-2018. Catheter Cardiovasc Interv 2019: 93 (Suppl 2), S166.

Zettler ME, Lieu HD, Almedhychy A.

Poster available upon request.

Patient-reported outcome labeling for cardiovascular drugs approved in the United States: 2011-2017. Circulation 2018: 138 (Suppl 1), A10649.

Zettler ME, Lieu HD.

Poster available upon request.

Read the abstract

Patient-reported outcome labeling for antidiabetic agents approved in the United States: 2011-2017. Diabetes 2018: 67 (Suppl 1), A344.

Zettler ME, Sandoval R.

Poster available upon request.

Read the abstract

Patient-reported outcome labeling for gastrointestinal drugs approved in the United States: 2011-2016. Gastroenterology 2018: 154 (6, Suppl 1), S999.

Zettler ME, Lim JD.

Poster available upon request.

Abstracts

Oncology

Rheumatology

Other